Some information about dementia

If you are aged above 65, and becoming forgetful, it could be possible that you are hit by dementia so get in touch with your doctor right now and talk about the problem. Memory loss is also a part of aging, stress or certain illness, but if it is affecting you on a daily basis, our research has shown it could be dementia.

At our website you will get a comprehensive knowledge about this disease, affecting people mostly after the age of 65.

According to our research, 1 in 3 people over 65 are affected by Dementia in UK. Another shocking fact is that two third of people affected by this disease are women. There is a huge increase in the number of patients suffering this disease because of increased longevity.


If a person has dementia, that means he must be having a group of symptoms affecting memory, thinking and social abilities. The most common symptoms  are:

  • Memory Loss
  • Difficulty in communication
  • Inappropriate behavior
  • Hallucinations
  • Mental agility
  • Depression
  • Periods of confusion
  • Change in personality and moods
  • Difficulty in planning and organising

The person suffering from Dementia may lose his feelings of compassion and understanding ability. According to our research, most types of dementia can be slowed down, if detected early.

Causes of dementia

The research team at did an extensive analysis to find out the causes of dementia. Dementia is a neurological disorder caused by damage to nerve cells. Depending on the area of brain that is impacted, this disease affects people differently. Dementia is progressive and there are various types of this disorder.

So, if you or your loved ones suffer from few of the symptoms listed, immediately consult your doctor. Or visit our website daily to get more information.

Know types of Dementia

Dementia belongs to the category of brain diseases, and impacts person’s ability to think and remember. It affects mostly the people aged above 65 and according to the current figures, globally 36 million people are impacted by Dementia.

There are various types of this progressive disease. Our research team conducted extensive research on various types of dementia and have listed the following main categories:

Alzheimers’s disease: This is the most common form of dementia, impacting a majority of US population. Symptoms such as memory loss and trouble planning and doing things are common symptoms of this type of dementia.

Vascular dementia: A silent stroke is the major cause of vascular dementia, causing memory impairments and other cognitive disabilities are  common  symptoms.

Dementia with Lewy Bodies: This type of dementia becomes common with age . Lewy bodies are clumps of protein that are found in brain. The unique features indicated by the experts at are hallucinations, tremor and memory trouble.

Frontotemporal dementia: Individuals suffering from this type of dementia have developed damage in areas of brain that control planning and judgment, emotions and speech.

Huntingdon’s disease: This is a genetic disorder, wherein signs start appearing during 30s or 40s. People experience personality changes and decline in cognitive skills.

Creutzfeldt-Jakob Disease: If your loved ones have twitching or jerky muscles,  our researchers have shown that they might be suffering from another type of dementia. This happens suddenly and gets worsen quickly.

Parkinson’s disease: Many people with Parkinson’s disease also suffer from dementia.

There could be various causes to this neurological disease and its various types. The team at has found that most common causes of dementia are nutritional deficiencies, reactions to some medicines, poisoning, metabolic problems like thyroid, brain infections, or brain tumor. So visit our website to get more information about dementia

Typical manifestation of dementia: would gradually increment

In the vast majority of the parts, dementia and Alzheimer influences individuals more than 60 years old. It happens infrequently in more youthful adults. The amnesia will gradually increment in seriousness until the individual won't perceive his own particular family.

Furthermore, the danger of building up this infection relentlessly increments as individuals develops older. Conduct issues are additionally a manifestation habitually seen in AD. An increment in carnal commute is likewise oftentimes seen in individuals with Alzheimer Disease. A typical manifestation of dementia which shows these side effects is called Alzheimer or Alzheimer's sickness.

Effects that demonstrates the only effect

Amnesia is not by any means the only side effect that will demonstrate in somebody with AD. The individual will begin habitually soliciting what the time from the day is and what day. He is not ready to name the right month or year of the date. In the end he won't perceive his own particular house and continually debilitating to go out. At the point when an individual looses introduction in individual, he is not ready to perceive his direct family any more. It is indispensable to note that apart from all the possibility that individuals display indications of mellow cognitive impedance, it doesn't generally prompt dementia.

Deliberate range of dementia

Along these lines side effects must be assessed deliberately so that legitimate analysis can be made which thusly ought to prompt the usage of accommodating treatment. Alzheimer sickness is useful for 70% of a wide range of dementia. With the help of our research at, the knowledge about the Alzheimer infection or termed as Commercial, which is a moderate disintegrating perspective where an individual gradually looses the capacity of distinctive mental procedures. By and large, this issue is degenerative and the side effects can't be switched. The progressions are perpetual and have a tendency to deteriorate over the long run. 

Over 65s at increased risk of developing dementia with benzodiazepine, study suggests

Patients over the age of 65 who begin taking benzodiazepine (a popular drug used to treat anxiety and insomnia) are at an approximately 50% increased risk of developing dementia within 15 years compared to never-users, a study published recently on the British Medical Journal website suggests.

The authors say that "considering the extent to which benzodiazepines are prescribed and the number of potential adverse effects indiscriminate widespread use should be cautioned against."

Benzodiazepine is a widely prescribed drug for the over 65s in many countries: 30% of this age group in France, 20% in Canada and Spain, 15% in Australia. Although less widespread in the UK and US it is still very widely used and many individuals take this drug for years despite guidelines suggesting it should be limited to a few weeks. Previous studies have found an increased risk of dementia, but others have been non-conclusive.

Researchers from France therefore carried out a study on 1063 men and women (average age 78) in France who were all free of dementia at the start. The study started in 1987 and follow-up was 20 years. The researchers used the first 5 years to identifying the factors leading to benzodiazepine initiation and evaluated then the association between new use of this drug and the development of dementia. They also assessed the association between further benzodiazepine initiation during the follow-up period and risk of subsequent dementia. Rates were adjusted for many factors potentially affecting dementia, such as age, gender, educational level, marital status, wine consumption, diabetes, high blood pressure, cognitive decline, and depressive symptoms.

95 out of the 1063 patients started taking benzodiazepine during the study. 253 (23.8%) cases of dementia were confirmed, 30 in benzodiazepine users and 223 in non-users. New initiation of the drug was associated with shorter dementia-free survival.

In absolute numbers, the chance of dementia occurring was 4.8 per 100 person years in the exposed group compared to 3.2 per 100 person years in the non-exposed group. A "person year" is a statistical measure representing one person at risk of development of a disease during a period of one year.

The authors say that although benzodiazepine remains useful for treating anxiety and insomnia, there is increasing evidence that its use may induce adverse outcomes in the elderly such as serious falls and fall-related fractures and this study may add dementia to the list. They say that their data add to the accumulating evidence that the use of benzodiazepines is associated with increased risk of dementia and, if true, that this "would constitute a substantial public health concern." Therefore, taken the evidence of potential adverse effects into account, physicians should assess expected benefits, limit prescriptions to a few weeks, and uncontrolled use should be cautioned against. They conclude that further research should "explore whether use of benzodiazepine in those under 65 is also associated with increased risk of dementia and that mechanisms need to be explored explaining the association"

Journal Reference:

  1. Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues J, Pérès K, Kurth T, Pariente A. Benzodiazepine use and risk of dementia: prospective population based study. BMJ, 2012; 345: e6231 DOI: 10.1136/bmj.e6231

Chewing ability linked to reduced dementia risk

Can you bite into an apple? If so, you are more likely to maintain mental abilities. (Credit: © Kzenon / Fotolia)

Can you bite into an apple? If so, you are more likely to maintain mental abilities, according to new research from Karolinska Institutet in Sweden.

The population is aging, and the older we become the more likely it is that we risk deterioration of our cognitive functions, such as memory, decision-making and problem solving. Research indicates several possible contributors to these changes, with several studies demonstrating an association between not having teeth and loss of cognitive function and a higher risk of dementia.

One reason for this could be that few or no teeth makes chewing difficult, which leads to a reduction in the blood flow to the brain. However, to date there has been no direct investigation into the significance of chewing ability in a national representative sample of elderly people.  

Now a team comprised of researchers from the Department of Dental Medicine and the Aging Research Center (ARC) at Karolinska Institutet and from Karlstad University in Sweden have looked at tooth loss, chewing ability and cognitive function in a random nationwide sample of 557 people aged 77 or older. They found that those who had difficulty chewing hard food such as apples had a significantly higher risk of developing cognitive impairments. This correlation remained even when controlling for sex, age, education and mental health problems, variables that are often reported to impact on cognition. Whether chewing ability was sustained with natural teeth or dentures also had no bearing on the effect.

The results are published in the Journal of the American Geriatrics Society (JAGS). The study was financed with grants from several funds, including the Swedish Council for Working Life and Social Research and the Swedish Research Council.


Journal Reference:

  1. Duangjai Lexomboon, Mats Trulsson, Inger Wårdh & Marti G. Parker. Chewing Ability and Tooth Loss: Association with Cognitive Impairment in an Elderly Population Study. Journal of the American Geriatrics Society, 2012

Eating lots of carbs, sugar may raise risk of cognitive impairment

People 70 and older who eat food high in carbohydrates have nearly four times the risk of developing mild cognitive impairment, and the danger also rises with a diet heavy in sugar, Mayo Clinic researchers have found. Those who consume a lot of protein and fat relative to carbohydrates are less likely to become cognitively impaired, the study found. The findings are published in the Journal of Alzheimer's Disease.

The research highlights the importance of a well-rounded diet, says lead author Rosebud Roberts, M.B., Ch.B., a Mayo Clinic epidemiologist.

"We think it's important that you eat a healthy balance of protein, carbohydrates and fat, because each of these nutrients has an important role in the body," Dr. Roberts says.

Researchers tracked 1,230 people ages 70 to 89 who provided information on what they ate during the previous year. At that time, their cognitive function was evaluated by an expert panel of physicians, nurses and neuropsychologists. Of those participants, only the roughly 940 who showed no signs of cognitive impairment were asked to return for follow-up evaluations of their cognitive function. About four years into the study, 200 of those 940 were beginning to show mild cognitive impairment, problems with memory, language, thinking and judgment that are greater than normal age-related changes.

Those who reported the highest carbohydrate intake at the beginning of the study were 1.9 times likelier to develop mild cognitive impairment than those with the lowest intake of carbohydrates. Participants with the highest sugar intake were 1.5 times likelier to experience mild cognitive impairment than those with the lowest levels.

But those whose diets were highest in fat — compared to the lowest — were 42 percent less likely to face cognitive impairment, and those who had the highest intake of protein had a reduced risk of 21 percent.

When total fat and protein intake were taken into account, people with the highest carbohydrate intake were 3.6 times likelier to develop mild cognitive impairment.

"A high carbohydrate intake could be bad for you because carbohydrates impact your glucose and insulin metabolism," Dr. Roberts says. "Sugar fuels the brain — so moderate intake is good. However, high levels of sugar may actually prevent the brain from using the sugar — similar to what we see with type 2 diabetes."

Even in normal range, high blood sugar linked to brain shrinkage

 People whose blood sugar is on the high end of the normal range may be at greater risk of brain shrinkage that occurs with aging and diseases such as dementia, according to new research published in the September 4, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology.

"Numerous studies have shown a link between type 2 diabetes and brain shrinkage and dementia, but we haven't known much about whether people with blood sugar on the high end of normal experience these same effects," said study author Nicolas Cherbuin, PhD, with Australian National University in Canberra.

The study involved 249 people age 60 to 64 who had blood sugar in the normal range as defined by the World Health Organization. The participants had brain scans at the start of the study and again an average of four years later.

Those with higher fasting blood sugar levels within the normal range and below 6.1 mmol/l (or 110 mg/dL) were more likely to have a loss of brain volume in the areas of the hippocampus and the amygdala, areas that are involved in memory and cognitive skills, than those with lower blood sugar levels. A fasting blood sugar level of 10.0 mmol/l (180 mg/dL) or higher was defined as diabetes and a level of 6.1 mmol/l (110 mg/dL) was considered impaired, or prediabetes.

After controlling for age, high blood pressure, smoking, alcohol use and other factors, the researchers found that blood sugar on the high end of normal accounted for six to 10 percent of the brain shrinkage.

"These findings suggest that even for people who do not have diabetes, blood sugar levels could have an impact on brain health," Cherbuin said. "More research is needed, but these findings may lead us to re-evaluate the concept of normal blood sugar levels and the definition of diabetes."

The study was supported by the National Health and Medical Research Council Australia and the Australian Rotary Health Research Fund.

Journal Reference:

  1. N. Cherbuin, P. Sachdev, K. J. Anstey. Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. Neurology, 2012; 79 (10): 1019 DOI: 10.1212/WNL.0b013e31826846de

Delirium has a dramatic impact on older people but is frequently undiagnosed

Delirium is widespread among older people but often goes ignored and untreated, according to new research by US and UK researchers including the University of East Anglia (UEA).

Published in the September issue of the Journal of Hospital Medicine, the findings show that delirium — or acute confusion — is common among older adults in hospitals and nursing homes. It has a negative impact on cognition and independence, significantly increases the risk of developing dementia, and triples the likelihood of death. Yet this common, acute condition is frequently either undiagnosed or accepted as inevitable.

Led by the Regenstrief Institute and Indiana University, the research team reviewed 45 years of research encompassing 585 studies. They found that one in three cases of delirium were preventable and are calling for delirium to be identified and treated early to prevent poor long-term prognosis.

"As a geriatric psychiatrist I have seen that around 50 per cent or people with dementia in hospital develop delirium," said co-author Dr Chris Fox, of Norwich Medical School at the University of East Anglia.

"This is because in addition to having dementia, they have multiple risk factors that can predispose and precipitate delirium — including serious illnesses and pre-existing cognitive impairment. In addition, hospital staff commonly label the signs as dementia related and do not pick up the delirium."

"We need to develop better mechanisms for diagnosing delirium so that prompt treatment regimes can be initiated."

In general patient groups, more than 60 per cent of delirium cases are not recognised or treated, and significant numbers of elderly patients leave hospital with ongoing delirium which has been missed.

The authors, led by Dr Babar Khan of the Regenstrief Institute and Indiana University School of Medicine, said that delirium could be prevented by eliminating restraints, treating depression, ensuring that patients have access to glasses and hearing aids, and prescribing classes of antipsychotics that do not negatively affect the aging brain. They also noted the need for a more sensitive screening tool for delirium, especially when administered by a non-expert.

"Delirium is extremely common among older adults in intensive care units and is not uncommon in other hospital units and in nursing homes, but too often it is ignored or accepted as inevitable," said Dr Khan. "Delirium significantly increases risk of developing dementia and triples likelihood of death. It cannot be ignored."

Co-author Dr Malaz Boustani, of the Regenstrief Institute, Indiana University School of Medicine and Wishard Healthy Aging Brain Center, said: "Having delirium prolongs the length of a hospital stay, increases the risk of post-hospitalization transfer to a nursing home, increases the risk of death and may lead to permanent brain damage."

'Delirium in Hospitalized Patients: Implications of Current Evidence on Clinical Practice and Future Avenues for Research — A Systematic Evidence Review' by Mohammed Zawahiri (Regenstrief Institute and IU Center for Aging Research), Noll L. Campbell (Regenstrief Institute, Purdue University and Wishard Health Services), Chris Fox (University of East Anglia), Eric Weinstein (Tri-State Pulmonary Associates), Arif Nazir (IU School of Medicine), Mark Farber (IU School of Medicine), John Buckley (IU School of Medicine), and Alasdair MacLullich (University of Edinburgh) is published online by the Journal of Hospital Medicine on September 18.

The study was supported by the National Institute on Aging and the National Institute of Mental Health.

Journal Reference:

  1. Mohammed Zawahiri et al. Delirium in Hospitalized Patients: Implications of Current Evidence on Clinical Practice and Future Avenues for Research — A Systematic Evidence Review. Journal of Hospital Medicine, 2012

Growth hormone-releasing hormone appears to aid cognitive functioning

Treatment with growth hormone-releasing hormone appears to be associated with favorable cognitive effects among both adults with mild cognitive impairment and healthy older adults, according to a randomized clinical trial published Online First by Archives of Neurology, a JAMA Network publication.

"Growth hormone-releasing hormone (GHRH), growth hormone and insulinlike growth factor 1 have potent effects on brain function, their levels decrease with advancing age, and they likely play a role in the pathogenesis of Alzheimer disease," the authors write as background information in the study.

To examine the effects of GHRH on cognitive function in healthy older adults and in adults with mild cognitive impairment (MCI), Laura D. Baker, Ph.D., of the University of Washington School of Medicine and Veterans Affairs Puget Sound Health Care System, Seattle, and colleagues, conducted a randomized, double-blind, placebo-controlled trial in which participants self-administered daily injections of a form of human GHRH (tesamorelin), or placebo.

The authors enrolled 152 adults ranging in age from 55 to 87 years (average age, 68 years) and 137 participants (76 healthy patients and 61 patients with MCI) successfully completed the study. At baseline, at 10 and 20 weeks of treatment, and after a 10-week washout (30 weeks total), the authors collected blood samples and administered parallel versions of cognitive tests.

Among the original 152 patients enrolled in the study, analysis indicated a favorable effect of GHRH on cognition, which was comparable in adults with MCI and healthy older adults. Analysis among the 137 patients who successfully completed the trial also showed that treatment with GHRH had a favorable effect on cognition among both groups of patients. Although the healthy adults outperformed those with MCI overall, the cognitive benefits relative to placebo was comparable among both groups.

Treatment with GHRH also increased insulinlike growth factor 1 levels by 117 percent, which remained within the physiological range, and increased fasting insulin levels within the normal range by 35 percent in adults with MCI but not in healthy adults.

"Our results replicate and expand our earlier positive findings, demonstrating that GHRH administration has favorable effects on cognitive function not only in healthy older adults but also in adults at increased risk of cognitive decline and dementia," the authors conclude. "Larger and longer-duration treatment trials are needed to firmly establish the therapeutic potential of GHRH administration to promote brain health in normal aging and 'pathological aging.'"

Journal Reference:

  1. Laura D. Baker, Suzanne M. Barsness, Soo Borson, George R. Merriam, Seth D. Friedman, Suzanne Craft, Michael V. Vitiello. Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial. Archives of Neurology, 2012; DOI: 10.1001/archneurol.2012.1970

Good news: Migraines hurt your head but not your brain

Migraines currently affect about 20 percent of the female population, and while these headaches are common, there are many unanswered questions surrounding this complex disease. Previous studies have linked this disorder to an increased risk of stroke and structural brain lesions, but it has remained unclear whether migraines had other negative consequences such as dementia or cognitive decline. According to new research from Brigham and Women's Hospital (BWH), migraines are not associated with cognitive decline.

This study is published online by the British Medical Journal (BMJ) on August 8, 2012. "Previous studies on migraines and cognitive decline were small and unable to identify a link between the two. Our study was large enough to draw the conclusion that migraines, while painful, are not strongly linked to cognitive decline," explained Pamela Rist ScD, a research fellow in the Division of Preventive Medicine at BWH, and lead author on this study.

The research team analyzed data from the Women's Health Study, a cohort of nearly 40,000 women, 45 years and older. In this study, researchers analyzed data from 6,349 women who provided information about migraine status at baseline and then participated in cognitive testing during follow-up. Participants were classified into four groups: no history of migraine, migraine with aura (transient neurology symptoms mostly of the visual field), migraine without aura, and past history of migraine. Cognitive testing was carried out in two year intervals up to three times.

"Compared with women with no history of migraine, those who experienced migraine with or without aura did not have significantly different rates of cognitive decline," explained Rist. "This is an important finding for both physicians and patients. Patients with migraine and their treating doctors should be reassured that migraine may not have long term consequences on cognitive function."

There is still a lot that is unknown about migraines. However this study offers promising evidence for patients and their treating physicians. More research needs to be done to understand the consequences of migraine on the brain and to establish strategies to influence the course of the disease in order to optimize treatment strategies.

This research was supported by The Women's Health Study is supported by grants from the National Heart, Lung, and Blood Institute (HL-043851, HL-080467, HL-099355) and the National Cancer Institute (CA-47988). The cognitive substudy of the Women's Health Study was supported by a grant from the National Institute of Aging (AG-15933). PMR was supported by a training grant from the National Institute of Aging (AG-00158). TK is supported in part by a Chair of Excellence grant of the French National Research Agency (Agence Nationale de la Recherche, R09177DD).

Journal Reference:

  1. P. M. Rist, J. H. Kang, J. E. Buring, M. M. Glymour, F. Grodstein, T. Kurth. Migraine and cognitive decline among women: prospective cohort study. BMJ, 2012; 345 (aug08 1): e5027 DOI: 10.1136/bmj.e5027